AzTrials
AzTrials

Obesity and OverweightPhase 2NCT06737042

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

A Phase 2 study testing GZR18 and Tirzepatide in people with Obesity and Overweight, run by Gan and Lee Pharmaceuticals, USA at 20 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2… Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Obesity and Overweight
What is being tested?
GZR18 and Tirzepatide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
326 participants
Where
20 sitesUnited States
Study dates
24 Feb 2025to 27 Feb 2026
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 to 75 years of age (both inclusive) at the time of signing the informed consent form (ICF).
  • History of failing to lose sufficient weight with lifestyle/dietary modification.
  • BMI ≥30.0 kg/m2, or
  • BMI ≥27.0 kg/m2 with at least 1 of the following:
  • Hypertension: defined as taking blood pressure (BP) lowering medication or have a systolic blood pressure (SBP) of ≥130 mmHg or a diastolic blood pressure (DBP) of ≥80 mmHg at screening.
  • Dyslipidemia: defined as taking lipid-lowering medication or have LDL ≥160 mg/dL (4.1 mmol/L) or triglycerides ≥150 mg/dL (1.7 mmol/L), or high-density lipoprotein (HDL) <40 mg/dL (1.0 mmol/L) for men or HDL <50 mg/dL (1.3 mmol/L) for women at screening.
Show all 13Show fewer
  • Obstructive sleep apnea.
  • Cardiovascular disease: defined as having eg, ischemic cardiovascular disease or New York Heart Association (NYHA) Functional Classification Class I to II heart failure.
  • 4. In the investigator's opinion, are well motivated, capable, and willing to:
  • Learn how to self-inject the IP as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the IP; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IP).
  • Inject the IP (or receive an injection from a trained individual if visually impaired or with physical limitations).
  • Follow study procedures for the duration of the study, including, but not limited to, lifestyle advice (eg, dietary changes and physical activity plan), complete the electronic diary (eDiary), and complete required questionnaires.
  • Identify the biological sex for the study stratification. 5.Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Who cannot join

  • A self-reported change (increase or decrease) in body weight >5 kg within 3 months prior to screening.
  • Prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed >1 year prior to screening).
  • Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening, including but not limited to:
  • Mucosal ablation
  • Gastric artery embolization
  • Intragastric balloon
Show all 92Show fewer
  • Duodenal-jejunal endoluminal liner Related to Diabetes
  • History of type 1 or T2DM, history of ketoacidosis, or hyperosmolar state/coma.
  • At least 1 laboratory value suggestive of diabetes during screening, including 1 or more of HbA1c ≥6.5% (48 mmol/mol), fasting serum glucose ≥126 mg/dL (7.0 mmol/L), or random glucose ≥200 mg/dL (11.1 mmol/L).
  • Other Medical Conditions
  • Renal impairment measured as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, calculated by chronic kidney disease-epidemiology collaboration (CKD-EPI) as determined by central laboratory during screening.
  • Known clinically significant gastric emptying abnormality (eg, severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility.
  • History of acute or chronic pancreatitis. A participant with a history of acute pancreatitis caused by gallstones may be included in the study if the participant has a cholecystectomy to resolve the problem.
  • Thyroid-stimulating hormone (TSH) outside of the range of 0.4 to 6.0 mIU/L at screening.
  • Note: Participants receiving treatment for hypothyroidism may be included, provided their thyroid hormone replacement dose has been stable for at least 6 months.
  • Note: TSH values above the normal range can, in some participant, suggest subclinical hypothyroidism. If, in the investigator's opinion, the participant has subclinical hypothyroidism and may require initiation of thyroid hormone replacement during the study, the participant should be excluded from the study.
  • Obesity induced by other endocrinologic disorders (eg, Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (eg, melanocortin 4 receptor deficiency or Prader-Willi syndrome).
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (eg, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years.
  • Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, in the opinion of the investigator, may be considered for inclusion if they are not on excluded medications.
  • A history of suicide attempt.
  • Patient health questionnaire-9 (PHQ-9) score of 15 or more at screening.
  • On the Columbia Suicide Severity Rating Scale (C-SSRS) prior to randomization:
  • a "yes" answer to Question 4 (active suicidal ideation with some intent to act, without specific plan) on the "suicidal ideation" portion of the C-SSRS or
  • a "yes" answer to Question 5 (active suicidal ideation with specific plan and intent) on the "suicidal ideation" portion of the C-SSRS or
  • a "yes" answer to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior) on the "suicidal behavior" portion of the C-SSRS and
  • the ideation or behavior occurred within the past month
  • Uncontrolled hypertension (SBP ≥160 mmHg and/or DBP ≥100 mmHg). If a participant is on antihypertensive therapies, doses must be stable for 30 days prior to screening. For participants with uncontrolled hypertension at screening, antihypertensive medication may be started or adjusted. BP must meet the protocol criterion for hypertension control with stable treatment for at least 30 days before re-screening.
  • An elevated resting pulse rate >100 bpm at baseline.
  • Any of the following cardiovascular conditions within 3 months prior to screening:
  • Acute myocardial infarction
  • Cerebrovascular accident (stroke)
  • Unstable angina
  • Hospitalization due to congestive heart failure (CHF)
  • Ongoing or history of frequent intermittent or chronic tachyarrhythmia syndromes (eg, atrial fibrillation, supraventricular tachycardia, and positional orthostatic tachycardia syndrome).
  • Note: Participants with a history of premature atrial contractions or premature ventricular contractions may be included.
  • NYHA Functional Classification III or IV CHF.
  • An electrocardiogram (ECG) considered by the investigator indicative of active cardiac disease or with abnormalities that may interfere with the interpretation of changes in ECG intervals at screening.
  • Acute or chronic hepatitis, or signs and symptoms of any other liver disease other liver disease except nonalcoholic fatty liver disease (NAFLD) (ie, participants with NAFLD are eligible for participation), or any of the following at screening:
  • alanine aminotransferase (ALT) >3 × the upper limit of normal (ULN)
  • alkaline phosphatase (ALP) >1.5 × ULN
  • total bilirubin level >1.5 × ULN (except for cases of known Gilbert's Syndrome)
  • Serum calcitonin level of:
  • 20 ng/L, if eGFR ≥60 mL/min/1.73 m2
  • 35 ng/L, if eGFR ≤60 mL/min/1.73 m2
  • A family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
  • A history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for <5 years.
  • Any other condition not listed in this section (eg, hypersensitivity or intolerance) that is a contraindication to GLP-1R agonists.
  • A history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the investigator, may preclude the participant from following and completing the protocol.
  • Alcohol consumption >14 units/week for women and >21 units/week for men.
  • A history of use of marijuana or tetrahydrocannabinol (THC)-containing products within 3 months of enrollment or unwillingness to abstain from marijuana or THC-containing product use during the study.
  • Note: If a participant has used cannabidiol oil during the past 3 months but agrees to refrain from use for the duration of the study, the participant may be enrolled.
  • Have had an organ transplant (corneal transplants [keratoplasty] are allowed) or are awaiting an organ transplant.
  • Any hematological condition that may interfere with HbA1c measurements (eg,
  • A blood donation of ≥500 mL within the previous 8 weeks of screening or a blood transfusion or severe blood loss within the prior 3 months, or have known hemoglobinopathy, hemolytic anemia, sickle cell anemia, or a hemoglobin value <11 g/dL (men) or <10 g/dL (women), or any other condition known to interfere with HbA1c methodology.
  • A history of atopy (severe or multiple allergic manifestations) or clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, anaphylaxis, angioedema, or exfoliative dermatitis).
  • A fasting serum triglyceride level of >500 mg/dL at screening. If a participant is on lipid-lowering therapies, doses must be stable for 30 days prior to screening.
  • Prior/Concomitant Therapy
  • Are receiving or have received within 3 months prior to screening chronic (>2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, single intraarticular injection, or inhaled preparations) or have evidence of a significant, active autoimmune abnormality (eg, lupus or rheumatoid arthritis) that has required (within the last 3 months) or is likely to require, in the opinion of the investigator, concurrent treatment with systemic glucocorticoids (excluding topical, intraocular, intranasal, intraarticular, or inhaled preparations) during the course of the study.
  • Receiving treatment with or have a history of treatment with (within 3 months prior to screening) medications that may cause significant weight gain including, but not limited to, tricyclic antidepressants, atypical antipsychotics, and mood stabilizers:
  • Examples:
  • imipramine
  • amitriptyline
  • mirtazapine
  • paroxetine
  • phenelzine
  • chlorpromazine
  • thioridazine
  • clozapine
  • olanzapine valproic acid and its derivatives
  • lithium Note: Selective serotonin reuptake inhibitors other than paroxetine are permitted.
  • Have taken within 3 months prior to screening medications (prescribed or over thecounter) or alternative remedies intended to promote weight loss.
  • Examples include, but are not limited to:
  • Saxenda® (liraglutide 3.0 mg) or other GLP-1R agonists
  • Xenical®/Alli® (orlistat)
  • Meridia® (sibutramine)
  • Acutrim® (phenylpropanolamine)
  • Sanorex® (mazindol)
  • Adipex® or LomairaTM (phentermine)
  • QsymiaTM (phentermine/topiramate combination)
  • Contrave® (naltrexone/bupropion)
  • Use of metformin or any other glucose-lowering medication, whether prescribed for polycystic ovarian syndrome or diabetes prevention is not permitted.
  • Have started implantable or injectable contraceptives (such as Depo Provera®) within 18 months prior to screening.
  • Prior/Concurrent Clinical Study Experience
  • Have known allergies to GLP-1R agonists or GZR18.
  • Are currently enrolled in any other clinical study involving an IP or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Within the last 30 days, participated in a clinical study and received treatment, whether active or placebo. If the study involved an IP, 5 half-lives or 30 days, whichever is longer, should have passed.
  • Have previously completed or withdrawn from this study or any other study investigating GZR18 and have previously received GZR18.
  • Other Exclusions
  • Women of childbearing potential (WOCBP) who:
  • Are pregnant or intend to become pregnant (or have a positive pregnancy test at screening).
  • Are lactating/breastfeeding (including the use of a breast pump).
  • Are unwilling to remain abstinent or use acceptable birth control

Trial locations and contacts

20 sites in 1 country.

20 sites in 1 country

United States20 sites

  • Elligo Clinical Research Center - Austin

    Austin, Texas, 78704

  • KUR Research - Trinity @ Bessemer, AL Site Network

    Bessemer, Alabama, 35022

  • KUR Research - Trinity @ Centreville Site Network

    Centreville, Alabama, 35042

  • Populace Health, LLC - CTI Clinical Research Center

    Cincinnati, Ohio, 45212

  • KUR Research @ Columbia Site Network

    Columbia, Maryland, 21045

  • ERG - Ohio Clinical Trials

    Columbus, Ohio, 43212

  • Ark Clinical Research Ark-Fountain Valley

    Fountain Valley, California, 92708

  • East Coast Institute for Research - ECIR Jacksonville (Southside)

    Jacksonville, Florida, 32216

  • East Coast Institute for Research ECIR Jacksonville (Headquarters) University

    Jacksonville, Florida, 32216

  • Clinvax Katy Research Center

    Katy, Texas, 77493

  • 3Sync Research - PCRS Network

    Lake Worth, Florida, 33460

  • Populace Health, LLC - Vector Clinical Trials

    Las Vegas, Nevada, 89128

  • ERG - Woodland Int'l Research Group

    Little Rock, Arkansas, 72211

  • Ark Clinical Research Ark-Long Beach

    Long Beach, California, 90815

  • Clever Medical Research - PCRS Network

    Miami, Florida, 33126

  • Clinedge - Central Valley Research, LLC

    Modesto, California, 95350

  • Populace Health, LLC - Catalina Research Institute

    Montclair, California, 91763

  • ERG - Woodland Research Northwest

    Rogers, Arkansas, 72758

  • Endeavor Clinical Trials

    San Antonio, Texas, 78229

  • Populace Health, LLC - Elixia SISU

    Springfield, Massachusetts, 01103

Other trials in United States

About this study

Official title: EFFICACY AND SAFETY OF GZR18 INJECTED EVERY 2 WEEKS (Q2W) IN PARTICIPANTS WITHOUT TYPE 2 DIABETES, WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, TIRZEPATIDE- AND PLACEBO-CONTROLLED STUDY

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).

Read the detailed description

This is a Phase 2 multicenter, randomized, parallel-group, partially-blinded, placebo and tirzepatide-controlled study of the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-related comorbidities (excluding type 2 diabetes mellitus).

The study will comprise a 2-week screening period (Days -14 to -1), a 36-week treatment period (Weeks 0 to 36), which includes a titration period and a maintenance dose period, and a safety follow-up period of 2 weeks after the primary endpoint assessment (ie, 4 weeks after the last GZR18 dose and 3 weeks after the last tirzepatide dose).

Approximately 285 participants will be randomized at Week 0 into 1 of 4 groups, stratified by sex. The study will be partially-blinded (intragroup blinded); treatment in the GZR18 groups will be blinded (GZR18 vs placebo), but GZR18 vs tirzepatide will be unblinded.

Being tested
GZR18, Tirzepatide
Keywords
GLP-1, Obesity, Overweight, Weight loss
Medical subject headings
Obesity, Overweight, Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06737042
Study groupRoleWhat they receive
24 mg GZR18 groupExperimental24 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
Receives: Drug: GZR18
36 mg GZR18 groupExperimental36 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
Receives: Drug: GZR18
48 mg GZR18 groupExperimental48 mg GZR18 group: 76 participants (57 receiving GZR18 and 19 receiving placebo)
Receives: Drug: GZR18
Tirzepatide groupActive comparatorTirzepatide group: 57 participants receiving 15 mg tirzepatide
Receives: Drug: Tirzepatide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Objective

    To demonstrate that GZR18 24 mg, 36 mg, and 48 mg is superior to placebo based on percentage change in body weight after 36 weeks of treatment

    Measured: 36 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2024
  2. Study start24 Feb 2025
  3. Primary completion27 Feb 2026
  4. Study completion27 Feb 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
326 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06737042
Sponsor's protocol ID
GL-GLP-2001
Status last verified
Jul 2026
First submitted
16 Dec 2024
Last updated
16 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing GZR18 and Tirzepatide in people with Obesity and Overweight, run by Gan and Lee Pharmaceuticals, USA at 20 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 92 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 20 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Objective (time frame: 36 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06737042.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in